Answers are grounded in this paper and cite their sources.
HP-3070, a once-daily asenapine transdermal system, is the first antipsychotic "patch" formulation FDA approved for adults with schizophrenia. Positive and Negative Syndrome Scale (PANSS) score items can be grouped into a five-factor structure to describe specific schizophrenia symptom domains. This post hoc analysis of data from a pivotal study evaluated HP-3070's efficacy by examining these factors.
No takes yet. Share an insight, caveat, or question.
Citrome et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: